在1926例晚期结直肠癌患者中全基因组搜索生存决定因素并在超过22000例患者中随访验证
该研究对COIN和COIN-B试验中1926例晚期结直肠癌患者进行全基因组关联分析寻找总生存相关SNP,最显著SNP为ERBB4基因rs79612564(HR=1.24,95%CI=1.16-1.32,P=1.9×10-7)。
要点
- ERBB4 rs79612564与晚期结直肠癌总生存相关(HR=1.24,95%CI=1.16-1.32,P=1.9×10-7)。
- 所有先导SNP在SOCCS和ISACC的meta分析中均未独立重复。
- 结肠腺癌中ERBB4高表达者生存更差(HR=1.50,95%CI=1.1-1.9,P=4.6×10-2)。
核心结论
- 遗传学和表达数据支持rs79612564在受体酪氨酸激酶ERBB4中作为生存预测生物标志物的潜在作用。
研究设计与样本
- 研究为全基因组关联分析,纳入COIN和COIN-B临床试验中1926例晚期结直肠癌患者。
- 对与总生存相关(P<1.0×10-5)的SNP,基于诊断至死亡时间进行敏感性分析。
- 在SOCCS的5675例患者和ISACC的16964例患者中寻求独立重复。
- 分析人类蛋白质图谱以确定ERBB4表达与438例结肠腺癌患者生存的关联。
主要发现
- 与总生存最显著相关的SNP为ERBB4基因rs79612564(HR=1.24,95%CI=1.16-1.32,P=1.9×10-7)。
- 17个基因座的SNP与总生存有提示性关联,且均对诊断至死亡时间有相似效应。
- 所有先导SNP在SOCCS和ISACC全部患者的meta分析中均未独立重复。
- rs79612564在SOCCS的IV期患者中显著(P=2.1×10-2),在ISACC中不显著(P=0.89);SOCCS联合COIN和COIN-B达全基因组显著性(P=1.7×10-8)。
- 结肠腺癌中ERBB4高表达患者生存更差(HR=1.50,95%CI=1.1-1.9,P=4.6×10-2)。
局限性
- 所有先导SNP在SOCCS和ISACC全部患者的meta分析中均未独立重复。
- rs79612564在ISACC中不显著(P=0.89)。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: While genome-wide association studies (GWAS) have identified germline variants influencing the risk of developing colorectal cancer (CRC), there has been limited examination of the possible role of inherited variation as a determinant of patient outcome. PATIENTS AND METHODS: We performed a GWAS for overall survival (OS) in 1926 patients with advanced CRC from the COIN and COIN-B clinical trials. For single nucleotide polymorphisms (SNPs) showing an association with OS (P < 1.0 × 10-5), we conducted sensitivity analyses based on the time from diagnosis to death and sought independent replications in 5675 patients from the Study of Colorectal Cancer in Scotland (SOCCS) and 16,964 patients from the International Survival Analysis in Colorectal cancer Consortium (ISACC). We analysed the Human Protein Atlas to determine if ERBB4 expression was associated with survival in 438 patients with colon adenocarcinomas. RESULTS: The most significant SNP associated with OS was rs79612564 in ERBB4 (hazard ratio [HR] = 1.24, 95% confidence interval [CI] = 1.16-1.32, P = 1.9 × 10-7). SNPs at 17 loci had suggestive associations for OS and all had similar effects on the time from diagnosis to death. No lead SNPs were independently replicated in the meta-analysis of all patients from SOCCS and ISACC. However, rs79612564 was significant in stage-IV patients from SOCCS (P = 2.1 × 10-2) but not ISACC (P = 0.89) and SOCCS combined with COIN and COIN-B attained genome-wide significance (P = 1.7 × 10-8). Patients with high ERBB4 expression in their colon adenocarcinomas had worse survival (HR = 1.50, 95% CI = 1.1-1.9, P = 4.6 × 10-2). CONCLUSIONS: Genetic and expression data support a potential role for rs79612564 in the receptor tyrosine kinase ERBB4 as a predictive biomarker of survival.
引用
- Wills C, He Y, Summers MG, et al. A genome-wide search for determinants of survival in 1926 patients with advanced colorectal cancer with follow-up in over 22,000 patients. Eur J Cancer. 2021. PMID: 34794066. doi:10.1016/j.ejca.2021.09.047
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。